A partial agonist of PPARγ; activates PPARγ with a lower potency (Ki = 15 versus 0.035 µM) but a similar maximal efficacy compared to rosiglitazone; improves insulin resistance in normal, diet-induced glucose-intolerant, and in diabetic db/db mice, yet reduced adipogenic activity.